Premium
Gd‐DOTA Conjugate of RGD as a Potential Tumor‐Targeting MRI Contrast Agent
Author(s) -
Park JiAe,
Lee JaeJun,
Jung JaeChang,
Yu DaeYeul,
Oh Chilhwan,
Ha Seunghan,
Kim TaeJeong,
Chang Yongmin
Publication year - 2008
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.200800529
Subject(s) - dota , conjugate , chemistry , pentapeptide repeat , mri contrast agent , cancer research , cytotoxicity , chelation , gadolinium , peptide , medicine , biochemistry , in vitro , mathematical analysis , mathematics , organic chemistry
Tumor recognition : Conjugation of 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA) with the cyclic pentapeptide c(RGDYK) and subsequent complexation with GdCl 3 ⋅ 6 H 2 O afforded Gd‐DOTA‐RGD, which, although a single molecular entity, is an efficient, target‐specific MRI contrast agent for the α ν β 3 receptors in hepatocellular carcinoma in H‐ ras 12V transgenic mice. The compound displays very low cytotoxicity and might hence warrant further study for clinical usage.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom